ARTICLE | Clinical News
Cytos CYT002-NicQb Phase II data
May 17, 2005 2:08 AM UTC
Cytos (SWX:CYTN) said that data from a double-blind, placebo-controlled, Swiss Phase II trial of CYT002-NicQb in 341 patients with nicotine addiction show a relationship between induced antibody level...